Table 2.

Clinical Features of 10 Patients With Multizonal Outer Retinopathy and Retinal Pigment Epitheliopathy (MORR)

Patient No./Sex/Age, y	Laterality	Follow-Up Duration, y	Initial Visual Acuity	Final Visual Acuity	Medical History	Systemic Work-Up and Genetic Testing	Treatment	Natural Course and Complications
1/F/43	Bilateral	23	20/20 OD 20/20 OS	20/30 OD 20/20 OS	Graves' disease	Negative laboratory and genetic panel testing	Mycophenolate mofetil	Centripetal and centrifugal progression with foveal sparing OU
2/F/71	Bilateral	17	20/25 OD 20/25 OS	20/40 OD 20/60 OS	Rheumatoid arthritis, hypertension, asthma	Negative laboratory and whole genome sequencing	None	Centripetal and centrifugal progression with foveal sparing OU
3/M/69	Bilateral with marked asymmetry	10	20/40 OD 20/30 OS	20/200 OD 20/50 OS	Hypercholesterolemia	Negative laboratory and genetic panel testing	None	Centripetal and centrifugal progression with foveal involvement OD Discrete progression of peripapillary lesion with foveal sparing OS
4/F/53	Bilateral with marked asymmetry	21	20/60 OD 20/20 OS	HM OD HM OS	Hashimoto thyroiditis, hypercholesterolemia	Negative laboratory and genetic panel testing	Acyclovir	Complete retinal degeneration OU
5/F/64	Bilateral	10	20/30 OD 20/40 OS	20/150 OD 20/200 OS	Hashimoto's thyroiditis, Type 1 diabetes, hypertension, liver hemangiomas, ovarian cancer	Negative laboratory and whole genome sequencing	None	Centripetal and centrifugal progression with foveal involvement OU
6/M/41	Bilateral	10	20/20 OD 20/20 OS	20/100 OD 20/100 OS	Ulcerative colitis, primary sclerosing cholangitis	Negative laboratory testing	Repeated IVI of dexamethasone implant 0.7 mg, then of fluocinolone acetonide intravitreal implant (0.19 mg)	Centripetal and centrifugal progression with foveal involvement OU. Temporary cessation of the peripapillary lesion progression and partial regression of the fringe-like hyperautofluorescent border after intravitreal corticosteroids Subretinal fibrosis OD
7/F/53	Bilateral	10	20/40 OD 20/20 OS	20/300 OD 20/40 OS	Congenital pulmonary valve disease, hypercholesterolemia, Type 2 diabetes	Negative laboratory and genetic panel testing	Repeated IVI of dexamethasone implant 0.7 mg, then of fluocinolone acetonide intravitreal implant (0.18 mg)	Centripetal and centrifugal progression with foveal involvement OD Temporary cessation of the peripapillary lesion progression and partial regression after repeated IVI of dexamethasone 0.7 mg then centripetal and centrifugal progression with foveal involvement OS
8/F/38	Bilateral	13	20/20 OD 20/200 OS	20/40 OD 20/400 OS	Unremarkable	Negative laboratory and genetic panel testing	Corticosteroid, mycophenolate mofetil, methotrexate, adalimumab, infliximab	Centripetal and centrifugal progression with foveal sparing OD and foveal involvement OS
9/F/40	Bilateral	8	20/20 OD 20/20 OS	20/20 OD 20/20 OS	Unremarkable	Negative laboratory testing	Corticosteroid, adalimumab	Centripetal and centrifugal progression with foveal sparing OU
10/F/69	Bilateral	9	20/20 OD 20/40 OS	20/200 OD 20/200 OS	Unremarkable	Negative laboratory and genetic panel testing	Intravitreal injections of bevacizumab	Centripetal and centrifugal progression with foveal involvement OU Choroidal neovascularization OS and subretinal fibrosis OU

IVI, intravitreal injection; OD, right eye: OS, left eye.